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Abstract 
OBJECTIVES: Accumulating evidence has underlined the importance of mucosal 
healing as a treatment goal for ulcerative colitis (UC). Quantitative fecal 
immunochemical tests (FITs), which can rapidly quantify fecal blood with automated 
equipment, have been used recently to screen for colorectal neoplasia. The aim of this 
study is to determine whether an FIT can evaluate mucosal healing in UC. 
METHODS: Feces collected from UC patients who underwent colonoscopy were 
examined by FITs, and results were compared with colonoscopic findings. Mucosal 
status was assessed using the Mayo endoscopic subscore classification. Maximum score 
for the colorectum in each patient was recorded. 
RESULTS: Evaluated were FIT results in conjunction with 310 colonoscopies that 
were performed in 152 UC patients. A large majority of patients with a Mayo 0 
endoscopic score had negative FIT (< 100 ng/ml) results (92%), and the proportion of 
negative FIT results decreased with increases in the Mayo score (Mayo 1: 47%, Mayo 
2: 13%, Mayo 3: 12%, p < 0.0001, Cochran-Armitage trend test). When the negative 
FIT was defined as < 100 ng/ml, the sensitivity and specificity of a negative FIT for 
mucosal healing (Mayo 0) were 0.92 and 0.71, respectively. When mucosal healing was 
defined as Mayo 0 or 1, those were 0.60 and 0.87, respectively. In addition, a positive 
FIT (> 100 ng/ml) predicted mucosal inflammation (Mayo 2 or 3) with sensitivity 0.87 
and specificity 0.60, respectively. 
CONCLUSIONS: The FIT can effectively and noninvasively evaluate mucosal healing 
in UC. This easy, rapid method can help evaluate and control disease activity of UC. 
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STUDY HIGHLIGHTS 
1. WHAT IS CURRENT KNOWLEDGE 
・Mucosal healing in ulcerative colitis (UC) is associated with sustained clinical 
remission and considered to be a treatment goal. 
・Confirmation of mucosal healing requires colonoscopy. 
・Quantitative fecal immunochemical tests (FITs) can quantify occult blood in many 
fecal samples and have been used to screen for colorectal neoplasia. 
・The use of FITs for evaluation of colon mucosa of UC patients has scarcely been 
reported. 
 
2. WHAT IS NEW HERE 
・FIT results effectively reflected the mucosal status in UC. 
・A negative FIT result could predict mucosal healing with sufficient sensitivity and 
specificity. 
・By making use of FIT, treatment strategy for UC patients could be determined in many 
situations without performing colonoscopy. 
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Introduction 
Ulcerative colitis (UC) is an idiopathic chronic inflammatory disorder that 
affects the innermost lining or mucosa of the colon and rectum, manifesting as 
continuous areas of inflammation and ulceration with no segments of normal tissue.(1) 
UC patients have symptoms such as diarrhea and bloody stool, unless appropriate 
treatment is provided. Aminosalicylates are the usual first-line treatment for UC, and 
60-70% of patients with mild to moderate UC respond to them. Corticosteroid treatment 
is considered in patients with more severe symptoms when aminosalicylates are not 
effective. However, intravenous steroids are not effective in 20-30% of patients, and 
these patients ultimately are likely to require colectomy.(2) 
Current opinions increasingly cite the need to achieve not only clinical 
response but also endoscopic mucosal healing in the treatment of UC. Mucosal healing 
is associated with sustained clinical remission, and reduced rates of hospitalization and 
surgical resection.(3) In addition, a recent study indicated that early mucosal healing 
after administration of infliximab for UC was correlated with improved clinical 
outcomes including avoidance of colectomy.(4) Another report showed that lack of 
mucosal healing after initial corticosteroid therapy was associated with late negative 
outcomes.(5) 
Although endoscopic evaluation is necessary for confirmation of mucosal 
healing, undergoing colonoscopy is invasive and burdensome to patients. In addition, 
the colonoscopic procedure can worsen the disease condition even in UC patients in 
remission.(6) Therefore, noninvasive methods of evaluating and predicting mucosal 
status are eagerly desired. Although it was previously reported that fecal calprotectin 
and lactoferrin could be useful markers of intestinal inflammation,(7) the measurements 
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of these materials are not simple and not available in all institutions. 
Quantitative fecal immunochemical tests (FITs) can measure hemoglobin 
concentrations in feces using an antibody for human hemoglobin. Such methods have 
been used to screen for colorectal neoplasia not only in Japan but Western countries 
instead of guaiac-based fecal occult blood tests.(8-10) In addition, FITs have the 
advantage of rapidly and simultaneously quantifying blood in many fecal samples with 
automated equipment.(8) The amount of fecal blood most likely reflects mucosal status 
in UC. In particular, occult blood can be present in feces of UC patients in clinical 
remission but without mucosal healing. Such fecal occult blood can be detected by FIT, 
and therefore, a negative FIT result may reflect and predict mucosal healing 
noninvasively. 
In this study, we measured fecal hemoglobin concentrations by FIT in UC 
patients who had undergone colonoscopy. The ability of FIT to indicate the mucosal 
status, particularly mucosal healing, was examined by comparing fecal hemoglobin 
concentrations with colonoscopic findings.  
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Materials and Methods 
Patients 
Ambulatory UC patients who periodically visited Okayama University 
Hospital were routinely requested to prepare and bring fecal samples at each visit 
beginning in 2006, in order to evaluate the amount of fecal occult blood with an FIT. 
All UC patients who underwent scheduled colonoscopy between January 2006 and 
August 2011 were considered eligible for this study. All of the patients had an 
established diagnosis of UC according to endoscopic and histologic assessments and 
had received medical therapy. In this study, we compared colonoscopic findings with 
FIT results obtained on the day of colonoscopy or within one month before colonoscopy. 
Patients who did not have FIT results within one month before colonoscopy and patients 
with changes in abdominal symptoms or treatment after the FIT but before colonoscopy 
were excluded from this study.  
Clinical disease activity was evaluated using the Mayo scores, consisting of the 
following 4 subscores: stool frequency (0, normal number for this patient; 1, 1-2 stools 
more than normal; 2, 3-4 stools more than normal; and 3, ≥ 5 stools more than normal), 
rectal bleeding (0, no blood seen; 1, streaks of blood with stool less than half the time; 2, 
obvious blood with stool most of the time; and 3, blood alone passes), endoscopic 
findings (0, normal or inactive disease; 1, mild disease with erythema, decreased 
vascular pattern, mild friability; 2, moderate disease with marked erythema, absent 
vascular pattern, friability, erosions; and 3, severe disease with spontaneous bleeding, 
ulceration), and physician’s global assessment (0, normal; 1, mild disease; 2, moderate 
disease; and 3,severe disease). (11) Clinical remission was defined as a Mayo stool 
frequency subscore of 0 or 1 and a Mayo rectal bleeding subscore of 0.(4) All other 
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patients were considered to have clinically active disease. The study protocol was 
approved by the institutional review board of Okayama University Graduate School of 
Medicine, Dentistry, and Pharmaceutical Sciences. Informed consent was obtained from 
each patient. 
Fecal sampling and instrument for FIT analysis 
Details of the method used for the FIT were described previously.(8, 9, 12) 
Briefly, patients prepared fecal samples on the morning of or the day before the clinic 
visit using an OC-Hemodia sampling probe (Eiken Chemical, Tokyo, Japan) provided 
by the manufacturer of the kit. An 8 cm × 2 cm test tube-shaped container holds the 
sampling probe. The patient inserts the probe into several different areas of stool and 
then firmly places it back into the tube to seal it. The probe tip with the fecal sample is 
suspended in a standard volume of hemoglobin-stabilizing buffer. Submitted stool 
samples were immediately processed and examined using OC-SENSOR neo (Eiken 
Chemical), which can accurately measure fecal hemoglobin concentration from 50 
ng/ml – 1000 ng/ml. Fecal specimens with a hemoglobin concentration over 1000 ng/ml 
were measured by dilution. On the other hand, fecal specimens with a hemoglobin 
concentration less than 50 ng/ml were categorized as one (0 – 50 ng/ml) because FIT 
results are inaccurate when the hemoglobin concentration is less than 50 ng/ml. In 
general, stools with a hemoglobin concentration more than several thousands ng/ml 
were recognized as bloody stools.(12)   
Colonoscopy 
On the day of the colonoscopy, patients received a polyethylene glycol-based 
or magnesium citrate-based electrolyte solution for bowel preparation according to the 
instructions for use. After the colonic lavage was finished, patients underwent the 
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colonoscopy. Patients were excluded if the colonoscopic examination was incomplete 
because of problems with the bowel preparation or if the colonoscope could not be 
inserted into the cecum.  
Mucosal status of UC was assessed using the Mayo endoscopic subscore 
classification. Evaluation was performed at each portion of the colorectum (cecum, 
ascending, transverse, descending, and sigmoid colon, and rectum), and the maximum 
score in the colorectum of each patient was used for analysis. Mucosal healing was 
defined as an endoscopy score of ‘0’, or ‘0 or 1’ throughout the colorectum.  
Statistical analysis 
Statistical analysis was conducted using the JMP program (version 9, SAS 
Institute, Cary, NC, USA). Spearman rank correlation was performed to determine the 
association between fecal hemoglobin concentrations and the Mayo endoscopic scores 
or the total Mayo score, and the trend between them was evaluated using the 
Cochran-Armitage trend test. Sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV), positive likelihood ratio, and negative likelihood ratio 
with 95% confidence intervals (CIs) for detecting mucosal status based on FIT results 
were determined. To estimate appropriate cutoff values for the FIT, receiver operating 
characteristic (ROC) curve analysis was performed. The predictive value of FIT versus 
mucosal healing on the risk of relapse was examined using Cox proportional hazards 
regression. All p values were two-sided and considered significant when less than 0.05. 
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Results 
Clinical characteristics of patients  
A total of 310 colonoscopies that were accompanied by corresponding FIT 
results were performed in 152 UC patients (77 men, 75 women; median age at UC onset 
30 years) (Table 1). Of 310 colonoscopy cases, 134 (43%) were performed in patients in 
clinical remission, while the other 176 (57%) were performed in patients with clinically 
active disease. Colonoscopy findings revealed that the maximum endoscopic subscore 
for the colorectum was Mayo 0 in 48 (15%) cases, Mayo 1 in 123 (40%) cases, Mayo 2 
in 106 (34%) cases, and Mayo 3 in 33 (11%) cases. Among 262 patients with 
endoscopic activity (Mayo 1-3), 162 (62%) had the maximum degree of mucosal 
inflammation in the rectum, 49 (19%) had in the sigmoid colon, and 51 (19%) had in 
the descending colon or more proximal part. On the other hand, FIT results indicated 
that more than one third of cases had fecal hemoglobin concentrations of 100 ng/ml or 
less (120/310, 39%), while approximately half of the remaining cases had fecal 
hemoglobin concentrations of more than 1000 ng/ml (106/310, 34%).  
Correlation between FIT results and colonoscopic findings 
The correlation between FIT results and colonoscopic findings is shown in 
Figure1. Spearman rank correlation coefficient and the corresponding p value for the 
correlation were 0.5409 and p < 0.0001, respectively. Since the cutoff value of 
hemoglobin concentration 100 ng/ml is usually used in colorectal cancer (CRC) 
screening,(13) the proportions of cases with hemoglobin concentration < 100 ng/ml 
were examined in relation to the Mayo score. The proportion of cases with hemoglobin 
concentration < 100 ng/ml was greatest in cases with Mayo 0 (44/48, 92%), and 
gradually decreased as the Mayo scores increased (Mayo 1: 58/123, 47%; Mayo 2: 
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14/106, 13%; and Mayo 3: 4/33, 12%). The trend of the decrease in relation to the Mayo 
endoscopic score was statistically significant (p < 0.0001, Cochran-Armitage trend test). 
This trend was similarly observed when analysis was restricted on patients with active 
disease (176 cases, Figure 1, red dots, p = 0.035) and when restricted on a single 
colonoscopy per patient (152 cases, Supplemental figure 1, p < 0.001). In addition to the 
correlation of FIT results with colonoscopic findings, the significant correlation 
between FIT results and disease activity (the total Mayo score) was observed 
(Supplemental figure 2, Spearman rank correlation coefficient = 0.70, p < 0.001). 
Sensitivity, specificity and predictive values of fecal hemoglobin concentration for 
mucosal status 
Table 2 shows the sensitivity, specificity, PPV, NPV, positive likelihood ratio, 
negative likelihood ratio and accuracy of the fecal hemoglobin concentration in relation 
to mucosal healing. When a negative FIT result was defined as < 100 ng/ml as in case 
of CRC screening, the sensitivity, specificity, PPV, NPV and accuracy of a negative FIT 
result for mucosal healing (Mayo 0) were 0.92, 0.71, 0.37, 0.97 and 0.74, respectively. 
Because the ROC curve indicated that 60 ng/ml was an optimal threshold (data not 
shown), those values in the case of a 60 ng/ml cutoff were 0.94, 0.74, 0.40, 0.98 and 
0.70, respectively. The analysis restricted on a single colonoscopy per patient showed 
slightly lower sensitivity (0.83, negative FIT < 100 ng/ml) and slightly higher 
specificity (0.83, negative FIT < 100 ng/ml) (Supplemental Table 1). The interval 
between FIT and colonoscopy did not affect significantly on the sensitivity and 
specificity (within 1 week, 1-3 weeks, and 3 weeks or more: sensitivity; 0.88, 0.91, and 
0.93, specificity; 0.74, 0.69, and 0.69, respectively). Analysis according to extent of 
disease revealed that the test performance on proctitis was somewhat low, compared to 
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other disease types (pancolitis, left-side colitis, and proctits: sensitivity; 0.93, 1.00, and 
0.67, specificity; 0.71, 0.76, and 0.68, respectively).  
Since the definition of mucosal healing has not definitely been established, we 
next determined the sensitivity, specificity etc. of a negative FIT for the Mayo 
endoscopic index 0 or 1 (Table 3). In this analysis, sensitivity was lower (0.60, negative 
FIT < 100 ng/ml) and specificity was higher (0.87, negative FIT < 100 ng/ml) than in 
case for the Mayo 0 only. In addition, as was expected, PPV was markedly higher (0.85, 
negative FIT < 100 ng/ml).  
In addition to the prediction of mucosal healing, the correlation between FIT 
results and endoscopically active diseases was examined (Table 4). The sensitivity and 
specificity of a positive FIT result (hemoglobin concentration > 100 ng/ml) for the 
Mayo endoscopic score 2 or 3 were 0.87 and 0.60, respectively. In this context, 
predictive power of a positive FIT result on the risk of relapse in clinically quiescent 
patients was determined using the Cox proportional hazards model. The hazard ratio of 
a positive FIT result (> 100 ng/ml) for relapse was 1.72 (95%CI 0.93-3.00, p = 0.061), 
while the ratio of endoscopically active diseases (Mayo 1-3) for relapse was 2.13 
(95%CI 1.16-4.24, p = 0.012). This suggests that a positive FIT result would be close to, 
but not go beyond endoscopic activity as the risk of relapse. 
 The predictive power of FIT results for mucosal status varied according to the 
definition of mucosal healing due to the skewed variation of endoscopic activities of our 
cohort. However, negative FIT results predicted mucosal healing with sufficient 
sensitivity and specificity, and therefore, UC patients in clinical remission with a 
negative FIT result could be regarded as being sufficiently treated. In contrast, a 
positive FIT result would imply the need of stricter follow-up. Thus, by making use of 
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FIT, treatment strategy for UC patients could be determined in many situations without 
performing colonoscopy.  
 
 
 
 
Nakarai et al. 14 
Discussion 
In this study, we compared FIT results and colonoscopy findings in UC patients, 
and found that FIT results accurately reflected the mucosal status in UC. In addition, a 
negative FIT result effectively predicted mucosal healing in UC. Therefore, FIT can be 
useful in evaluating mucosal healing after remission induction therapy. Moreover, 
because repeated evaluations of mucosal healing are required over the duration of UC, 
the noninvasive, low-cost, and rapid FIT is a suitable method that can be applied at each 
patient’s hospital or clinic visit. Its use would be helpful in reducing the burden of 
undergoing colonoscopy to confirm mucosal healing. 
After the accumulation of evidence for the value of mucosal healing in Crohn’s 
disease (CD),(14, 15) mucosal healing also has also been regarded as an important 
clinical goal in UC. Studies of infliximab have played important roles in establishing 
evidence of mucosal healing in the field of UC as well as in CD. The follow-up study of 
the Active UC Trials showed that mucosal healing after 8 weeks of infliximab was 
correlated with improved clinical outcomes including avoidance of colectomy.(4) 
Moreover, several additional studies indicated that mucosal healing in UC can alter the 
course of UC with reductions in hospitalization rates and surgical resections,(16) and by 
lowering the risk of dysplasia and adenocarcinoma of the colon.(16-18) A recent report 
showed that lack of mucosal healing after the first corticosteroid therapy was associated 
with late negative outcomes.(5) 
Thus, achieving mucosal healing in UC has become an important clinical goal. 
However, evaluation of mucosal healing by endoscopy is burdensome for patients. In 
addition to the colonoscopy procedure itself, bowel preparations, possible worsening of 
disease after colonscopy, and high cost are all matters of concern to patients. Moreover, 
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because repeated confirmation of mucosal healing is required over the long term, 
patients must undergo repeated colonoscopies. To overcome the most problematic 
clinical point in evaluating mucosal healing, surrogate noninvasive markers of mucosal 
healing have been explored. 
Although results using blood markers, including C-reactive protein, have been 
disappointing in predicting mucosal healing as well as in evaluating clinical activity of 
UC,(19) fecal calprotectin, a major protein found in the cytosol of inflammatory cells, 
has been examined extensively to determine its correlation with disease status of IBD 
and was found to be the only marker to predict activity of UC as shown by endoscopy. 
Schoepher et al. reported that fecal calprotectin values were more closely correlated 
with the Rachmilewitz endoscopic activity index than clinical symptoms or blood 
markers, and showed that the fecal calprotectin with cuttoff values of > 50 μg/g had the 
best performance in sensitivity (93%), specificity (71%), PPV (91%), NPV (81%), and 
accuracy (89%) for detection of endoscopically active disease (defined as Rachmilewitz 
Endoscopic Activity Index > 4).(20)  
Thus, fecal calprotectin was shown to be an effective pioneer as a fecal marker 
of mucosal healing in UC.(20) However, FIT has several advantages in comparison 
with fecal calprotectin. First, FIT is simpler and less costly. To measure fecal 
calprotectin, 5 – 10 g of stool is required, while the FIT requires only insertion of a 
probe into the stool, making it more user friendly and possibly resulting in better 
compliance. The dietary restriction that is required in guaiac-based fecal occult blood 
tests but not with the FIT makes the latter test more accessible to UC patients. 
The cost of each FIT is minimal and mainly limited to the cost of the collecting 
tube, although the automated equipment (OC-Sensor neo at our institution) is rather 
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expensive, usually costing tens of thousands of dollars. However, this equipment is also 
used for CRC screening. Therefore, at least in Japan, tertiary medical centers, including 
our institute, usually have such equipment. The FIT for UC patients is probably 
available even in smaller institutes, including general practices, because many low-cost 
manual kits for FIT are available, although such kits cannot quantify fecal hemoglobin. 
However, qualitative methods could be substituted for the testing equipment described 
in this report, because sensitivity of each manual kit corresponds to a unique cutoff 
value of a quantitative method. Cutoff values we used in this study (60 – 100 ng/ml) are 
those usually used in CRC screening,(9, 21) and therefore, the sensitivity of the majority 
of manual kits would be similar to ours.  
The rapidity of the FIT is another advantage. Automated FIT equipment can 
usually measure more than 100 samples in a few minutes, while measurement of fecal 
calprotectin requires the enzyme-linked immunosorbent assay technique,(22) which 
usually takes several hours. Therefore, FIT can be easily performed for many 
outpatients before a doctor’s visit, and helpful for evaluating disease activity of patients 
in a short time.        
When mucosal healing was defined as Mayo 0, the sensitivity, specificity, and 
NPV of the FIT was equal to fecal calprotectin as shown previously but the PPV was 
relatively lower for mucosal healing. The PPV could be comparable when mucosal 
healing was defined as Mayo 0 or 1. In our study, we adopted the Mayo endoscopic 
index in evaluating of mucosal status, while Schoepher et al.(20) adopted Rachimilewitz 
endoscopic index < 4 as mucosal healing. The difference in definitions of mucosal 
healing may have brought about the difference in sensitivity, specificity etc. In future 
studies, comparison of the ability to detect mucosal healing between fecal calprotectin 
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and FIT should be performed using the same cohort and the same definition of mucosal 
healing.  
There are limitations to this study. First, we adopted the 1-day method of FIT, 
in which stool is collected for only 1 day. In CRC screening, stool collection for 2 or 3 
days is usually recommended as superior to a single collection in terms of sensitivity for 
colorectal neoplasia.(23-25) In this study that targeted mucosal healing in UC patients, 
the FIT examination of 2 or 3 fecal samples may have raised sensitivity to slight 
mucosal inflammation. Consequently, the examination of multiple samples might 
reduce the proportion of negative FIT results in patients with a Mayo 1 endoscopic 
index, and therefore, specificity and PPV for Mayo 0 only of negative FIT results may 
be improved. Second, the FIT cannot be used in women during menstruation as the 
value of fecal hemoglobin concentration may be inaccurate. Lastly, we did not examine 
mucosal healing in CD patients, although that had been done with fecal 
calprotectin.(26) Because detection of bleeding in the small intestine by the FIT has not 
been definitely determined, patients with CD involving only the colon may be a target 
for FIT in future studies.      
In conclusion, our study revealed that FIT results effectively reflected the 
mucosal status in UC and that a negative FIT was strongly correlated with mucosal 
healing. This noninvasive, easy, low-cost and rapid method can help in the evaluation 
and control of disease activity in UC. In addition, our findings indicated an important 
new application for FIT in addition to CRC screening. 
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Figure Legends 
Figure 1. Correlation between fecal hemoglobin concentrations and colonoscopic 
findings.  
The fecal hemoglobin level was positively correlated with endoscopic activity 
(Spearman rank correlation coefficient = 0.5409, p < 0.0001). The proportion of cases 
with a hemoglobin concentration < 100 ng/ml was greater in cases with Mayo 0 (92%), 
and the proportions were gradually decreased with increases in the Mayo endoscopic 
subscore (Mayo 1: 47%, Mayo 2: 13%, and Mayo 3: 12%). The trend of a decrease in 
the proportion of negative results according to increases in the Mayo subscore was 
statistically significant (p < 0.0001, Cochran-Armitage trend test). This trend was 
similarly observed when analysis was restricted on patients with active disease (176 
cases , red dots, p = 0.035). 
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Table 1. Characteristics of study patients, colonoscopy findings and results of fecal 
immunochemical tests 
 
Total     152
Median (range) age at onset     30 (4-80)
Gender
   Male     77 (51%)
   Female     75 (49%)
Number of colonoscopy
    1     74 (49%)
    2     23 (15%)
    ≥3     55 (36%)
Extent of disease
   Pancolitis     98 (65%)
   Left-side colitis     31 (20%)
   Proctitis     23 (15%)
Total     310
Median (range) duration of disease, months          135 (0.57-487)
Median (range) age of  undergoing colonoscopy      31 (4-71）
Median (range) intreval between FIT and colonoscopy, days      16 (1-29）
Clinical activity
   Remission stage   134 (43%)
   Active stage   176 (57%)
Purpose of colonoscopy
   Evaluation of disease   138 (45%)
   Surveillance   172 (55%)
Concomitant medications
    Aminosalicylate    291 (94%)
    Corticosteroids      75 (24%)
    Mercaptopurine/Azathioprine    129 (42%)
    Tacrolimus    10 (3%)
Colonoscopy findings (maximum index in the colorectum）
    Mayo 0      48 (15%)
    Mayo 1    123 (40%)
    Mayo 2    106 (34%)
    Mayo 3      33 (11%)
Fecal hemoglobin concentrations (ng/ml)
     0 - 50    110 (36%)
     51 - 100    10 (3%)
    101 - 1000      84 (27%)
    1001 - 10000      87 (28%)
    10001 -    19 (6%)
Patients
Colonoscopy
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Table 2. Sensitivity, specificity, and predictive values of fecal immunochemical tests 
for mucosal healing (Mayo endoscopic score 0) 
 
 
                 Fecal Hb concentration ＜100 ng/ml Fecal Hb concentration ＜60 ng/ml
0.92 ( 0.84-0.99 ) 0.94 ( 0.87-1.00 )
Specificity (95% CI) 0.71 ( 0.65-0.76 ) 0.74 ( 0.69-0.79 )
PPV (95% CI) 0.37 ( 0.28-0.45 ) 0.40 ( 0.31-0.49 )
NPV (95% CI) 0.97 ( 0.96-1.00 ) 0.98 ( 0.97-1.00 )
Accuracy (95% CI) 0.74 ( 0.69-0.79 ) 0.70 ( 0.72-0.82 )
Positive likelihood ratio 3.16 ( 2.63-3.44 ) 3.48 ( 2.88-3.80 )
Negative likelihood ratio 0.12 ( 0.05-0.27 ) 0.11 ( 0.05-0.26 )
Sensitivity (95% CI)
 
 
Hb, hemoglobin; PPV, positive predictive value; NPV, negative predictive value;  
CI, confidence interval 
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Table 3. Sensitivity, specificity, and predictive values of fecal immunochemical tests 
for mucosal healing (Mayo endoscopic score 0 or 1) 
 
 
Fecal Hb concentration ＜100 ng/ml                 Fecal Hb concentration ＜60 ng/ml
0.60 ( 0.55-0.63 ) 0.58 ( 0.54-0.61 )
Specificity (95% CI) 0.87 ( 0.82-0.91 ) 0.90 ( 0.85-0.94 )
PPV (95% CI) 0.85 ( 0.79-0.90 ) 0.88 ( 0.82-0.92 )
NPV (95% CI) 0.64 ( 0.60-0.67 ) 0.64 ( 0.60-0.66 )
Accuracy (95% CI) 0.72 ( 0.67-0.77 ) 0.72 ( 0.67-0.77 )
Positive likelihood ratio 4.61 ( 3.04-7.17 ) 5.75 ( 3.57-9.56 )
Negative likelihood ratio 0.46 ( 0.41-0.55 ) 0.47 ( 0.42-0.54 )
Sensitivity (95% CI)
 
 
Hb, hemoglobin; OR, odds ratio; CI, confidence interval 
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Table 4. Sensitivity, specificity, and predictive values of fecal immunochemical tests 
for endoscopically active diseases (Mayo endoscopic score 2 or 3) 
 
Fecal Hb concentration ≥ 100 ng/ml                Fecal Hb concentration ≥ 120 ng/ml
0.87 ( 0.82-0.91 ) 0.86 ( 0.80-0.90 )
Specificity (95% CI) 0.60 ( 0.55-0.63 ) 0.62 ( 0.58-0.66 )
PPV (95% CI) 0.64 ( 0.60-0.67 ) 0.65 ( 0.61-0.68 )
NPV (95% CI) 0.85 ( 0.79-0.90 ) 0.84 ( 0.78-0.89 )
Accuracy (95% CI) 0.72 ( 0.67-0.77 ) 0.73 ( 0.68-0.78 )
Positive likelihood ratio 2.16 ( 1.83-2.47 ) 2.25 ( 1.89-2.61 )
Negative likelihood ratio 0.22 ( 0.14-0.33 ) 0.23 ( 0.15-0.34 )
Sensitivity (95% CI)
 
Hb, hemoglobin; OR, odds ratio; CI, confidence interval 
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